<DOC>
	<DOCNO>NCT00002296</DOCNO>
	<brief_summary>The objective Phase III , randomize , double-blind , placebo-controlled study patient immunologic deficiency determine effect Isoprinosine produce immuno-restorative response within study observation period ( include 2-month period follow cessation 28 day treatment ) , measure one follow immunological parameter : - Increase natural killer ( NK ) cell activity . - Increase total T-cells ( OKT-11 ) . - Increases absolute number percentage T-helper cell ( OKT-4 ) .</brief_summary>
	<brief_title>The Safety Effectiveness Isoprinosine Patients With Weakened Immune Systems Lymph Node Disease</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphatic Diseases</mesh_term>
	<mesh_term>Inosine Pranobex</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition : Patients follow excluded : History gout , uric acid urolithiasis , uric acid nephrolithiasis , renal dysfunction severe gastric ulcer . Lymphoid malignancy . Infectious mononucleosis cause cytomegalovirus EpsteinBarr virus . Heart disease ( especially receive cardiac glycoside ) . Hemophilia . Patients follow exclude : Kaposi 's sarcoma overt opportunistic infection follow : Candida albicans , Pneumocystis carinii , Herpes simplex , Cryptococcus neoformans , Histoplasma capsulatum , Mycobacterium aviumintracellulare , Toxoplasma gondii , Legionella , Cryptosporidium , Isospora , Papovavirus . Active evidence infectious mononucleosis cause EpsteinBarr virus ( EBV ) cytomegalovirus ( CMV ) determine heterophil test ( EBV ) cell culture ( CMV ) . History gout , uric acid urolithiasis , uric acid nephrolithiasis , renal dysfunction , severe gastric ulcer . Critical illness . Condition require hospitalization . Women childbearing age exclude . Hemophilia . Prior Medication : Excluded : Steroids . Cytotoxic immunosuppressive agent . Antiviral medicine . Prior Treatment : Excluded : Radiotherapy . Patients unexplained immunodepression risk develop AIDS . Patients prolong generalize lymphadenopathy 3 month ( great 1 cm two noncontiguous site ) . IV drug abuse .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 1989</verification_date>
	<keyword>T-Lymphocytes</keyword>
	<keyword>Immune Tolerance</keyword>
	<keyword>Inosine Pranobex</keyword>
	<keyword>Killer Cells</keyword>
	<keyword>T-Lymphocytes , Helper-Inducer</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>